| Updated:

The British Business Bank said it has had to “throw the kitchen sink at the problem” of financing Britain’s life sciences sector in a bid to draw in further investment from pension funds and help domestic firms scale in the UK.
The state lender’s financial backing for the sector has reached £1.1bn, including £832m spread across 20 life science funds, alongside £302m ploughed into numerous domestic scale-ups, to try and increase the size of funding rounds.
Recent investments included £25m in Alchemab Therapeutics, its biggest financial support provided to a life science firm to date, and £15m to Cambridge university spinout T-Therapeutics.
Hiking pension investment
Speaking to City AM, the bank’s chief investment officer, Leandros Kalisperas said the state lender had to “throw the kitchen sink at the problem” of financing life sciences as it works to encourage more investment from pension funds.
The bank has been attempting to entice institutional investors, including signatories of the Mansion House accord, to unlock further pension capital for private assets and venture capital firms, including those that invest in the life sciences sector.
The accord saw 11 of the UK’s top pension money managers commit to investing five per cent of their assets in private markets and unlisted equities by 2030.
“Backing life science innovation adds extra complexity. We are aiming…to communicate the possibilities for pension funds themselves to get involved,” Kalisperas said.
A recent update revealed that the vast majority of committed capital for UK private markets has been allocated to property, amounting to 70 per cent of the total £11.1bn.
In contrast, just £500m was invested into private equity.
Overseas assistance and AI cycle
The sector has also long been plagued by acquisitions and relocations driven by overseas buyers, who promise better funding and scaling conditions.
Companies from the bank’s portfolio have also not been immune to this trend. US pharmaceutical giant Merck & Co acquired ophthalmology biotech firm Eyebio in a deal worth up to $3bn (£2.2bn) in 2024, while Japanese medical technology company Terumo snapped up Oxford University spinout Orgonox for $1.5bn last year.
But Chris Molloy, chief executive of the Bio Industry Association, said the increase in funding from the bank would “enable our most promising businesses to scale and stay in the UK”.
The lender also confirmed it committed €58m (£48.3m) to Sofinnova Crossover Fund II, a Parisian based fund which backs firms across Europe.
While the British Business Bank’s focus is on supporting domestic growth, Kalisperas said the state cannot rely solely on UK-only funds to attract deep pools of capital for specialist firms.
“You can’t back venture in the UK by just investing in managers that only invest in the UK,” he said.
“Within life sciences we have to acknowledge that there are European specialists in this space. We have to encourage them to invest in UK companies. Why wouldn’t we as a limited partner want them to do that?”
Looking ahead, Kalisperas expects investors to shift more capital into the sector as the AI cycle matures and products begin to implemented by real-world industries disconnected from the sector.
“People are going to be taking another look at life sciences because it is also linked in with AI… drug discovery can change through AI,” he added.
“I think there are a number of angles through which life sciences are hopefully going to get their moment.”
Canary Wharf development
The bank’s funding commitment follows the National Wealth Fund investing in one of London’s flagship science developments earlier this week.
It committed £147m of debt financing towards One North Quay in Canary Wharf, which will act as one of the “largest commercial science” buildings in Europe and address the lack of availability of specialist facilities needed to undertake research.
The financing is expected to fund the development of the project which is set to be completed in 2028. Barclays and Emirates NBD also pledged capital to the development, bringing the total to £368.5m.
Business, Innovation, Science and Trade Secretary, Jonathan Reynolds, said: “The UK is a genuine world-leader in life sciences, and One North Quay… will bolster that reputation.”


